KPV is about as small as a signalling peptide gets — three amino acids, written lysine-proline-valine, or K-P-V in the single-letter code. What makes it interesting is where it comes from: it is the very tail end of alpha-MSH, a natural hormone with well-known anti-inflammatory effects. Researchers found that this tiny three-letter fragment keeps much of the parent hormone's calming activity. It is studied mainly for inflammation in the gut and skin.
In plain terms: the anti-inflammatory "business end" of a natural hormone, shrunk to three amino acids — promising in the lab, unproven in people.
What it is
Alpha-MSH (alpha-melanocyte-stimulating hormone) is a hormone best known for affecting skin pigment, but it also acts as a broad anti-inflammatory signal in the body. Its anti-inflammatory power is concentrated in its last three amino acids: KPV. Isolate just those three, and you get a much simpler molecule that still calms inflammation in study models — without the pigment-related effects of the full hormone.
Because KPV comes from a melanocortin hormone, you will sometimes see it described as a melanocortin-derived tripeptide2.
How it works: calming from the inside
KPV's reported action is anti-inflammatory, and the interesting part is where it acts. Rather than only working at receptors on the cell surface, studies suggest KPV is taken up into cells and reduces inflammatory signalling from within — dialling down pathways such as NF-kB, a master switch that turns on inflammatory genes1.
The route in matters. A transporter called PepT1, which normally ferries small peptides across the gut lining, appears to carry KPV into intestinal and immune cells. PepT1 is switched on in inflamed gut tissue — so in principle KPV could concentrate exactly where inflammation is worst1.
In plain terms: it slips inside cells and turns down the inflammation switch — and it may ride a transporter that is busiest in inflamed tissue.
Pharmacokinetics: short-lived
KPV is a tripeptide, and tripeptides are broken down quickly by the body's enzymes. It has no long half-life (the time for half a dose to clear) and no established human pharmacokinetic profile, because it has not been through human pharmacokinetic trials. Much of the delivery research, in fact, focuses on protecting KPV or targeting it to tissue precisely because free KPV does not last long3.
What the studies actually found
KPV's evidence is a tight, consistent preclinical story centred on inflammatory bowel disease models. Note the species and level in every row:
| Study | Model / level | Key result | Year |
|---|---|---|---|
| Dalmasso et al.1 | Cells + mice (colitis) | KPV entered cells via PepT1 and reduced intestinal inflammation | 2008 |
| Kannengiesser et al.2 | Mice (two colitis models) | Reduced inflammation in both models, partly independent of the MC1R receptor | 2008 |
| Xiao et al.3 | Cells + mice (ulcerative colitis) | KPV-loaded targeted nanoparticles healed gut lining and eased inflammation at a far lower dose | 2017 |
The pattern is clear and worth stating plainly: consistent anti-inflammatory results in cell cultures and mouse colitis models12, plus delivery work showing that packaging KPV can make it far more potent in mice3. Every one of these is preclinical. None is a human trial.
In plain terms: a clean, repeatable animal story for gut inflammation — and no human efficacy evidence yet.
Handling and format
KPV is supplied for research as a lyophilised (freeze-dried) powder that is reconstituted before use, kept cold and out of light once mixed — standard peptide-handling practice. Some skin-focused research explores it in topical form, reflecting its interest for inflammatory skin conditions. This page explains what KPV is and what the studies showed, not how to use it, and takes no position on sourcing.
The honest limitations
- Every efficacy result is preclinical — cell cultures and mouse models, not human trials.
- The strongest, most repeated data is specifically for gut inflammation (colitis); skin uses are earlier-stage.
- Much of the promising potency depends on special delivery systems (nanoparticles) in animals, not plain KPV.
- It is a research compound, not an approved medicine anywhere.
Latest research
- The 2008 PepT1 study remains the mechanistic cornerstone — it explained both what KPV does (reduces inflammatory signalling) and how it gets into cells1.
- The 2017 nanoparticle work is the most notable recent advance: targeting KPV to inflamed gut tissue made it effective at a dramatically lower dose in mice, pointing to where the field is heading — smarter delivery, not just the raw peptide3.
- Controlled human trials are still absent. That gap is the single most important honesty point for KPV in 2026. We update this section if interventional human data appears.
The short version
KPV is a three-amino-acid peptide (lysine-proline-valine) taken from the anti-inflammatory tail of the hormone alpha-MSH. In cell and mouse studies it calms inflammation — most clearly in colitis models — apparently by entering cells via the PepT1 transporter and turning down inflammatory signalling. All the efficacy evidence is preclinical, with no controlled human trials, and it is a research compound, not a medicine. Educational overview only. For context, see what are research peptides.